Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046369 | 0.85 | DRD2 (0.52) | DRD2SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL19546253 | 0.85 | DRD2 (0.52) | DRD2SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL681521 | 0.85 | — | — | |
| SCHEMBL6512381 | 0.85 | DRD2 (0.52) | DRD2SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL384210 | 0.85 | DRD2 (0.52) | DRD2SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL294114 | 0.83 | DRD2 (0.43) | DRD2SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL27491836 | 0.82 | GNAI3 (0.57) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL6659994 | 0.82 | DRD2 (0.50) | DRD2SIGMAR1GNAI3GNAO1GNAI1 | |
| Ammonia Solution, Strong SCHEMBL9858529 | 0.82 | — | — | |
| Bromide SCHEMBL6660052 | 0.79 | DRD2 (0.48) | DRD2SIGMAR1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-05-21 | — | — | US | claimed |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-31 | — | — | US | claimed |
| US-9670242-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-06 | — | — | US | claimed |
| EP-2824108-B1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO LTD (CN) | 2017-04-19 | — | — | EP | claimed |
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2015-06-18 | — | — | US | claimed |
| EP-2824108-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2015-01-14 | — | — | EP | claimed |
| CN-104125962-A | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY BIO TECH CO LTD | 2014-10-29 | — | — | CN | claimed |
| US-4958024-A | REACTION OF CARBAMATE SUBSTITUTED ACRYLIC ESTER, VASODILATORS, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-09-18 | — | — | US | claimed |
| US-4914227-A | FOR VASODILATING AND HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-04-03 | — | — | US | claimed |
| US-4739106-A | VASODILATION, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | claimed |
| EP-0101023-B1 | PROCESS FOR PREPARING 2-CARBAMOYLOXYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND INTERMEDIATES USEFUL FOR THE PROCESS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-07-29 | — | — | EP | claimed |
| EP-0101023-A1 | Process for preparing 2-carbamoyloxyalkyl-1,4-dihydropyridine derivatives and intermediates useful for the process | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1984-02-22 | — | — | EP | claimed |
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-05-21 | — | — | US | disclosed |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| US-9670242-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-06 | — | — | US | disclosed |
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-4739106-A | VASODILATION, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| EP-0101023-B1 | PROCESS FOR PREPARING 2-CARBAMOYLOXYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND INTERMEDIATES USEFUL FOR THE PROCESS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-07-29 | — | — | EP | disclosed |
| EP-0215435-A1 | 2-Oxa-isocephem compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-25 | — | — | EP | disclosed |
| EP-0101023-A1 | Process for preparing 2-carbamoyloxyalkyl-1,4-dihydropyridine derivatives and intermediates useful for the process | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | DRD2 3001/4885SIGMAR1 3686/4885GNAI3 1534/4885 |
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, ANTXR2 | DRD2 3114/4885SIGMAR1 4369/4885GNAI3 1098/4885 |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | DRD2 3001/4885SIGMAR1 3686/4885GNAI3 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.